Literature DB >> 11127844

Primary prevention of neural-tube defects and some other major congenital abnormalities: recommendations for the appropriate use of folic acid during pregnancy.

A E Czeizel1.   

Abstract

Neural-tube defects (NTDs) are common and serious congenital abnormalities of the central nervous system. Although some cases of NTDs are induced by hyperhomocysteinaemia, resulting from genetic polymorphism of a thermolabile enzyme, in the majority of cases the cause is unknown. Diet supplementation with a folic acid-containing multivitamin or high dose of folic acid alone in the periconception period reduced the recurrence of NTDs by 83 to 91% and 71%, respectively. Two Hungarian intervention studies demonstrated a high efficacy for periconception multivitamin supplementation (containing a physiological dose: 0.8mg of folic acid) in the primary prevention of the first occurrence of an NTD (approximately 92% reduction in the incidence of NTDs). However, a high dose of folic acid (approximately 6mg) alone during the periconception period was less efficient. Periconception folic acid-containing multivitamin supplementation reduces the occurrence of urinary tract and cardiovascular congenital abnormalities, and congenital limb deficiencies. The occurrence of orofacial cleftings may also be reduced by a high dose of folic acid. This preventive effect may be the result of other mechanisms of action (e.g. compensation of impaired mitosis caused by a folate deficiency). There are 3 options for ensuring appropriate multivitamin/folic acid consumption for women of childbearing age. First, providing a folate- and other vitamin-rich diet, which unfortunately may not be appropriate for this purpose. Second, and perhaps the best choice, the unique opportunity for multivitamin/folic acid supplementation during the periconception period. However, a major proportion of pregnancies are unplanned and, even in planned pregnancies, this type of primary prevention has not been widely used. Furthermore, it would require changes to the previous recommendations since a multivitamin containing a physiological dose of folic acid (0.5 to 0.8mg) seems to be more effective in reducing the occurrence of the first NTD and other congenital abnormalities than folic acid alone. Periconception multivitamin supplementation may also reduce the occurrence of recurrent NTDs. Thirdly, food (e.g. flour, bread) may be fortified with folic acid or 3 B vitamins (folic acid, B 12 and B6). This provides a practical means to ensure all women, especially those from lower socioeconomic backgrounds and/or with a low level of education who are more likely to have unplanned pregnancies, have an adequate folic acid intake.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127844     DOI: 10.2165/00128072-200002060-00003

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  62 in total

1.  Does periconceptional multivitamin use reduce the risk for limb deficiency in offspring?

Authors:  Q Yang; M J Khoury; R S Olney; J Mulinare
Journal:  Epidemiology       Date:  1997-03       Impact factor: 4.822

2.  Prevention of neural tube defect recurrences in Yorkshire: final report.

Authors:  R W Smithells; S Sheppard; J Wild; C J Schorah
Journal:  Lancet       Date:  1989-08-26       Impact factor: 79.321

3.  Defects in human methionine synthase in cblG patients.

Authors:  S Gulati; P Baker; Y N Li; B Fowler; W Kruger; L C Brody; R Banerjee
Journal:  Hum Mol Genet       Date:  1996-12       Impact factor: 6.150

Review 4.  Evidence for multi-site closure of the neural tube in humans.

Authors:  M I Van Allen; D K Kalousek; G F Chernoff; D Juriloff; M Harris; B C McGillivray; S L Yong; S Langlois; P M MacLeod; D Chitayat
Journal:  Am J Med Genet       Date:  1993-10-01

5.  Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects.

Authors:  B Christensen; L Arbour; P Tran; D Leclerc; N Sabbaghian; R Platt; B M Gilfix; D S Rosenblatt; R A Gravel; P Forbes; R Rozen
Journal:  Am J Med Genet       Date:  1999-05-21

6.  The effect of folic acid fortification on plasma folate and total homocysteine concentrations.

Authors:  P F Jacques; J Selhub; A G Bostom; P W Wilson; I H Rosenberg
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

7.  Folate levels and neural tube defects. Implications for prevention.

Authors:  L E Daly; P N Kirke; A Molloy; D G Weir; J M Scott
Journal:  JAMA       Date:  1995-12-06       Impact factor: 56.272

8.  Periconceptional multivitamin use in relation to the risk of congenital urinary tract anomalies.

Authors:  D K Li; J R Daling; B A Mueller; D E Hickok; A G Fantel; N S Weiss
Journal:  Epidemiology       Date:  1995-05       Impact factor: 4.822

9.  Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring.

Authors:  G M Shaw; C D O'Malley; C R Wasserman; M M Tolarova; E J Lammer
Journal:  Am J Med Genet       Date:  1995-12-04

10.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more
  17 in total

Review 1.  Preconception care: a systematic review.

Authors:  Carol C Korenbrot; Alycia Steinberg; Catherine Bender; Sydne Newberry
Journal:  Matern Child Health J       Date:  2002-06

2.  Effect of chronic alcohol exposure on folate uptake by liver mitochondria.

Authors:  Arundhati Biswas; Sundar Rajan Senthilkumar; Hamid M Said
Journal:  Am J Physiol Cell Physiol       Date:  2011-09-28       Impact factor: 4.249

3.  Maternal nutritional deficiencies and interventions.

Authors:  C N Purandare
Journal:  J Obstet Gynaecol India       Date:  2012-12

4.  Health state preference scores of children with spina bifida and their caregivers.

Authors:  John M Tilford; Scott D Grosse; James M Robbins; Jeffrey M Pyne; Mario A Cleves; Charlotte A Hobbs
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

5.  Choline, not folate, can attenuate the teratogenic effects ofdibutyl phthalate (DBP) during early chick embryo development.

Authors:  Rui Wang; Da-Guang Sun; Ge Song; Chun Yi Guan; Yi Cui; Xu Ma; Hong-Fei Xia
Journal:  Environ Sci Pollut Res Int       Date:  2019-08-12       Impact factor: 4.223

6.  Crooked tail (Cd) model of human folate-responsive neural tube defects is mutated in Wnt coreceptor lipoprotein receptor-related protein 6.

Authors:  Michelle Carter; Xu Chen; Bozena Slowinska; Sharon Minnerath; Sara Glickstein; Lei Shi; Fabien Campagne; Harel Weinstein; M Elizabeth Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-26       Impact factor: 11.205

7.  Maternal exposure to outdoor air pollution and congenital limb deficiencies in the National Birth Defects Prevention Study.

Authors:  Giehae Choi; Jeanette A Stingone; Tania A Desrosiers; Andrew F Olshan; Wendy N Nembhard; Gary M Shaw; Shannon Pruitt; Paul A Romitti; Mahsa M Yazdy; Marilyn L Browne; Peter H Langlois; Lorenzo Botto; Thomas J Luben
Journal:  Environ Res       Date:  2019-09-10       Impact factor: 6.498

8.  Identification of dynein light chain road block-1 as a novel interaction partner with the human reduced folate carrier.

Authors:  Balasubramaniem Ashokkumar; Svetlana M Nabokina; Thomas Y Ma; Hamid M Said
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-01       Impact factor: 4.052

9.  Awareness and use of folic acid among reproductive age and pregnant women.

Authors:  Gülengül N Köken; Aysel Uysal Derbent; Onur Erol; Nimet Saygın; Hülya Ayık; Mehmet Karaca
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-06-01

10.  Differentiation-dependent regulation of the intestinal folate uptake process: studies with Caco-2 cells and native mouse intestine.

Authors:  Veedamali S Subramanian; Jack C Reidling; Hamid M Said
Journal:  Am J Physiol Cell Physiol       Date:  2008-07-23       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.